Literature DB >> 32611793

Prevalence of Mycoplasma genitalium and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium Assays for Diagnosis.

Ingibjörg Hilmarsdóttir1,2, Eva Mjöll Arnardóttir3,2, Elísabet Reykdal Jóhannesdóttir4, Freyja Valsdóttir3, Daniel Golparian5, Ronza Hadad5, Hannes Bjarki Vigfússon3, Magnus Unemo5.   

Abstract

Mycoplasma genitalium is prevalent among attendees in sexually transmitted infection (STI) clinics, and therapy is hampered by rapidly rising levels of resistance to azithromycin and moxifloxacin. In this study, we evaluated, for the first time in Iceland, the prevalence of M. genitalium and azithromycin and moxifloxacin resistance-associated mutations and assessed the diagnostic performance of the CE/in vitro diagnosis (IVD)-marked S-DiaMGTV (Diagenode Diagnostics) versus the U.S. FDA/CE/IVD-approved Aptima MG (AMG; Hologic) for M. genitalium detection. From October 2018 to January 2019, urine and vaginal swabs were provided by male and female attendees at Iceland's only STI clinic. Specimens were tested with S-DiaMGTV and AMG, and resistance-associated mutations were determined by 23S rRNA gene and parC sequencing. Demographic and clinical data were collected from patient records. M. genitalium prevalence was 9.3% overall; 7.7% (38/491) among male and 10.9% (53/487) among female participants. Azithromycin and moxifloxacin resistance-associated mutations were found in 57.0% (45/79) and 0.0% (0/80) of evaluable specimens, respectively. Sensitivity was 72.5% and 100%, and specificity was 99.9% and 100% for S-DiaMGTV and AMG, respectively. No association was found between M. genitalium and symptoms of urethritis in men. Prevalence rates for M. genitalium and azithromycin resistance-associated genes in Iceland are among the highest reported in Europe. The significantly higher sensitivity of AMG over that of S-DiaMGTV can have important clinical implications. More information is urgently needed to clarify the significance of false-negative results obtained with S-DiaMGTV and other similarly performing widely used real-time PCR methods for diagnosis and management of this sexually transmitted infection.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  23S rRNA; Iceland; antimicrobial resistance; azithromycin; moxifloxacin; parCzzm321990; urethritis

Mesh:

Substances:

Year:  2020        PMID: 32611793      PMCID: PMC7448636          DOI: 10.1128/JCM.01084-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Evaluation of two commercial real-time PCR assays for detection of Mycoplasma genitalium in urogenital specimens.

Authors:  Chloé Le Roy; Sabine Pereyre; Cécile Bébéar
Journal:  J Clin Microbiol       Date:  2013-12-26       Impact factor: 5.948

2.  The first performance report for the Bio-Rad Dx CT/NG/MG assay for simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in urogenital samples.

Authors:  Chloé Le Roy; Isabelle Le Hen; Maïthé Clerc; Véronique Arfel; Françoise Normandin; Cécile Bébéar; Bertille de Barbeyrac
Journal:  J Microbiol Methods       Date:  2012-03-15       Impact factor: 2.363

Review 3.  Mycoplasma genitalium: Accurate Diagnosis Is Necessary for Adequate Treatment.

Authors:  Charlotte A Gaydos
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

4.  Mycoplasma genitalium and Trichomonas vaginalis in France: a point prevalence study in people screened for sexually transmitted diseases.

Authors:  S Pereyre; C Laurier Nadalié; C Bébéar
Journal:  Clin Microbiol Infect       Date:  2016-11-09       Impact factor: 8.067

5.  Design and Validation of Transcription-Mediated-Amplification Nucleic Acid Amplification Tests for Mycoplasma genitalium.

Authors:  Brett Kirkconnell; Barbara Weinbaum; Katherine Santos; Trisha Le Nguyen; Bryan Vinluan; Sabina Astete; Gwendolyn E Wood; Patricia A Totten; Damon K Getman
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

6.  Clinical Laboratory Assessment of Mycoplasma genitalium Transcription-Mediated Amplification Using Primary Female Urogenital Specimens.

Authors:  Erik Munson; Holly Bykowski; Kimber L Munson; Maureen Napierala; Pamela J Reiss; Ronald F Schell; Jeanne E Hryciuk
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

7.  Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey.

Authors:  Kirsten Salado-Rasmussen; Jørgen Skov Jensen
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079

8.  Prevalence and antibiotic resistance of Mycoplasma genitalium among STI clinic attendees in Western Canada: a cross-sectional analysis.

Authors:  Jennifer Gratrix; Sabrina Plitt; LeeAnn Turnbull; Petra Smyczek; Judith Brandley; Ron Scarrott; Prenilla Naidu; Penny Parker; Brenda Blore; Amy Bull; Sandy Shokoples; Lindsay Bertholet; Irene Martin; Max Chernesky; Ron Read; Ameeta Singh
Journal:  BMJ Open       Date:  2017-07-10       Impact factor: 2.692

Review 9.  Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis.

Authors:  Lukas Baumann; Manuel Cina; Dianne Egli-Gany; Myrofora Goutaki; Florian S Halbeisen; Gian-Reto Lohrer; Hammad Ali; Pippa Scott; Nicola Low
Journal:  Sex Transm Infect       Date:  2018-02-09       Impact factor: 3.519

10.  Epidemiology of Mycoplasma genitalium in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Authors:  Pam Sonnenberg; Catherine A Ison; Soazig Clifton; Nigel Field; Clare Tanton; Kate Soldan; Simon Beddows; Sarah Alexander; Rumena Khanom; Pamela Saunders; Andrew J Copas; Kaye Wellings; Catherine H Mercer; Anne M Johnson
Journal:  Int J Epidemiol       Date:  2015-12       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.